CN104815243A - Preparation method of external washing liquid for atrophic vaginitis - Google Patents
Preparation method of external washing liquid for atrophic vaginitis Download PDFInfo
- Publication number
- CN104815243A CN104815243A CN201510279340.7A CN201510279340A CN104815243A CN 104815243 A CN104815243 A CN 104815243A CN 201510279340 A CN201510279340 A CN 201510279340A CN 104815243 A CN104815243 A CN 104815243A
- Authority
- CN
- China
- Prior art keywords
- parts
- washing liquid
- external washing
- atrophic vaginitis
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of an external washing liquid for atrophic vaginitis and aims at solving the treatment problem of the atrophic vaginitis. The external washing liquid is characterized in that 10-30 parts of oriental variegated coralbean bark, 6-12 parts of herb of smallflower bracketplant, 3-10 parts of fruit of tall gastrodia, 6-12 parts of flower bud of tianmu mountain magnokia, 3-10 parts of Chinese taxillus twig, 6-12 parts of root of catclaw buttercup, 6-12 parts of baked malt, 6-12 parts of baked medicated leaven, 6-12 parts of ephedra root, 1-5 parts of Chinese honeylocust spine, 3-10 parts of peach gum and 10-25 parts of cassia twig are mixed and decocted with water, a filtrate is separated 30 minutes later; the dregs of the decoction is added with water and is decocted further for 20 minutes and then the filtrate is obtained, and finally, the two filtrates are mixed to obtain the external washing liquid. Clinical experiments prove that the external washing liquid has the characteristics of good curative effect and relatively high safety when used for treating the atrophic vaginitis. The external washing liquid is worthy of clinical application and popularization.
Description
Technical field
The present invention is that (application number: divisional application 2013102678096), relates to the field of Chinese medicines is specifically related to a kind of powder preparation method for the treatment of atrophic vaginitis in application for a patent for invention " a kind of powder preparation method for the treatment of atrophic vaginitis ".
Background technology
Atrophic vaginitis is a kind of nonspecific vaginitis, be common in postclimacteric elderly woman, because of ovarian failure, the a lot of level of estrogen reduces, vaginal wall atrophy, and mucosa is thinning, in epithelial cell, glycogen content reduces, intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.Inspection is shown in that vagina is senile change, epithelial atrophy, and pleat disappears, and epithelium flattens sliding, poor.Vaginal mucosa is congested, has little petechia, sometimes sees shallow table ulcer.
Therapeutic Principle is for increasing the growth and breeding of vagina resistance and anti-bacteria.Current western medical treatment mostly is supplementary a small amount of estrogen, vaginal mucosa can be made to thicken, build up resistance.But estrogenic unreasonable use easily causes carcinoma of endometrium and breast carcinoma, so there is dispute in this kind of therapeutic scheme always.Bacteria growing inhibiting is then for put into antibiotic powder in intravaginal, but life-time service can cause local flora to be lacked of proper care, and causes larger puzzlement.
And the colpitic suppository of Chinese traditional treatment, outer lotion are many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of atrophic vaginitis mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the lotion of the little treatment atrophic vaginitis of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of atrophic vaginitis lotion preparation method, it is characterized in that: by Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Flos Magnoliae Amoenae 6 ~ 12 parts, Herba Taxilli 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Ramulus Cinnamomi 10 ~ 25 parts of mixing and water addings decoctions, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges and obtains lotion.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.Merit can heat-clearing and toxic substances removing; Dissipating blood stasis stops blooding.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.Merit can tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; Wind syndrome of head is had a headache; Weak breath consumption of essence; Early whitening of beard and hair.
Flos Magnoliae Amoenae, is Magnoliaceae head Drymotaenium miyoshianum (Mak.) Mak. Magnolia amoena Cheng, is used as medicine with alabastrum.Nature and flavor are bitter, cold.Merit can diuresis, detumescence, nourishing the lung to arrest cough.
Herba Taxilli, for Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser.Nature and flavor bitter, sweet, flat.Return liver, kidney channel.Merit can invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Ranunculi Ternati is the dried root of ranunculaceae plant Seynuns Kugelann Ranunculus ternatus Thunb..Nature and flavor sweet, acrid, warm.Return liver, lung meridian.Merit can eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven of fermentation, fry to burnt brown according to frying method.Nature and flavor sweet, acrid, warm.Enter spleen, stomach warp.Merit can invigorating the spleen and regulating the stomach, helps digestion in adjusting.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, flat.GUIXIN, lung meridian.Merit can hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are pungent, temperature.Return liver, stomach warp.Merit can be subsided a swelling poison holding, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant Fructus Persicae Prunus persica (L.) Batsch, the resin that trunk flows out.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Ramulus Cinnamomi is the dry twig of canella Cortex Cinnamomi Cinnamomum cassia Presl.Nature and flavor acrid, sweet, warm.GUIXIN, lung, urinary bladder channel.Merit can diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.
Composition principle: atrophic vaginitis is common in postclimacteric elderly woman, because of ovarian failure, the a lot of level of estrogen reduces, vaginal wall atrophy, mucosa is thinning, and in epithelial cell, glycogen content reduces, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.The colpitic suppository of current Chinese traditional treatment, outer lotion are many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of atrophic vaginitis mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.The object of the invention is to avoid using dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, vaginal wall atrophy, mucosa this pathological change angle thinning is started with, and reaches the object of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in side, go back bobbin for monarch, the Cortex erythrinae dosage recorded in " China's book on Chinese herbal medicine " is: " for oral administration: to decoct soup, 6-12g "; Inventor to test in proof heavy dose of Cortex erythrinae (10 ~ 30g) and can recover by specific promotion vaginal wall mucosa, and goes back bobbin and have similar plants estrogen action, but this act as two-ways regulation, can not produce the low differentiation of estrogen excessive stimulation reproductive system cell;
2, characteristic of the present invention is also balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbid ", but gerontal patient's resembling often with deficiency of YIN-blood, and now use Cortex erythrinae, then have and fear its hematozemia and cause yin asthenia generating intrinsic heat to occur; Therefore add Herba Chlorophyti Laxi and go back bobbin, also bobbin merit can train base by tonify deficiency, and can prevent Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize on the one hand it coldly to prevent heated, its merit can dissipating blood stasis hemostasis on the other hand, has out entire merit in blood system, prevent Cortex erythrinae to wander away dynamic blood, also can not affect Cortex erythrinae works orderly effect simultaneously; 2. in we, the use of Ramulus Cinnamomi is: a promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, two Yin Yang balancings, to balance the bitter cold of our invasion by pathogenic cold medicine of a cold nature thing; In prescription of the present invention, the application characteristic of Ramulus Cinnamomi is: measure larger (consumption in " Chinese Pharmacopoeia " is 3 ~ 9g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, supplementary drug thing is fewer but better: get Flos Magnoliae Amoenae assistant in side and help Herba Chlorophyti Laxi, heat conduction is descending; Radix Ranunculi Ternati and Herba Chlorophyti Laxi are arranged in pairs or groups the effect of removing toxic substances, eliminating stagnation, pain relieving; Herba Taxilli assistant helps goes back bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and contributes to drag residence in mucomembranous surface, penetration enhancement;
4, inventor's clinical research finds, solid protection gastric qi contributes to the atrophic vaginitis course of disease and controls and recover, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite;
5, Spina Gleditsiae is supplementary drug thing, record in " China book on Chinese herbal medicine " consumption be: " for oral administration: to decoct soup, 6 ~ 12g ", the present inventor's experimental study finds, gets low dose of Spina Gleditsiae decocting liquid and can improve in vitro vaginal mucosa cytoactive;
6, the homogeneous medicine multiple-effect of institute's thing of getting it filled in side, contributes to reducing medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, and each raw material dosage is for all to have good curative effect in following weight parts scope;
8, the fruit that bobbin is orchid Rhizoma Gastrodiae is gone back, compared with Rhizoma Gastrodiae, going back the Esterified Enzyme isozyme (esterase isoenzyme) that bobbin contains, may be that it plays the key of phytoestrogen effect, and inventor's experiment draws, it is higher that decompression goes back bobbin Esterified Enzyme isozyme content after decocting.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Flos Magnoliae Amoenae 10g, Herba Taxilli 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Ramulus Cinnamomi 20g.
The preparation method of embodiment 1 is: by Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Flos Magnoliae Amoenae, Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, the decoction of Ramulus Cinnamomi mixing and water adding, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, crude drug weight proportion: Cortex erythrinae 10 parts, Herba Chlorophyti Laxi 6 parts, go back 3 parts, bobbin, Flos Magnoliae Amoenae 6 parts, Herba Taxilli 3 parts, Radix Ranunculi Ternati 6 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Massa Medicata Fermentata (parched to brown) 6 parts, Radix Ephedrae 6 parts, Spina Gleditsiae 1 part, gumshiraz 3 parts, Ramulus Cinnamomi 10 parts.
Embodiment 3, crude drug weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Flos Magnoliae Amoenae 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Ramulus Cinnamomi 20 parts.
Embodiment 4, crude drug weight proportion: Cortex erythrinae 30 parts, Herba Chlorophyti Laxi 12 parts, go back 10 parts, bobbin, Flos Magnoliae Amoenae 12 parts, Herba Taxilli 10 parts, Radix Ranunculi Ternati 12 parts, Fructus Hordei Germinatus (parched to brown) 12 parts, Massa Medicata Fermentata (parched to brown) 12 parts, Radix Ephedrae 12 parts, Spina Gleditsiae 5 parts, gumshiraz 10 parts, Ramulus Cinnamomi 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
In prioritization scheme, the pressure of the distilling under reduced pressure in described step (1) is 0.1Mpa; The pressure that decompression in described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in described step (4) is 0.4Mpa.
The efficient combination of said medicine, coordinates mutually, effectively reach the object for the treatment of atrophic vaginitis, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case selection: be diagnosed as atrophic vaginitis 160 example in February, 2011 ~ in June, 2013, at 49 years old ~ 69 years old age, be menopausal women, be limited to 1 year ~ 20 years menopause.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all cases is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is xerosis vulae, pale or the flushing of vaginal mucosa or have little petechia, vaginal health scoring <15 divides, serum follicle stimulating hormone (FSH) >=40IU/L, serum estradiol (E2)≤110pmol/L, abdominal ultrasound examination endometrium thickness <5mm.All patients all carry out vaginal secretions inspection before the treatment and get rid of trichomonal vaginitis, monilial vaginitis, and urine is cultivated negative, without vulvar dystrophy and dermatosis.All cases get rid of hormone-dependent tumor, do not accept hormone medicine treatment over nearly 3 months.
1.1.3 divide into groups: be divided into matched group 53 example, washout group 53 example and powder group 54 example.Compare in age, the state of an illness, the course of disease before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: matched group adopts 1% lactic acid solution washout, the red and swollen significantly local of pudendum uses antibiotic Emulsion, 1 time/d.Washout group with gained decoct washout in the embodiment of the present invention 1,1 time/d.Powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the present invention 3,1 time/d.It within 14 days, is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after medication, and according to vaginal health point system (VHS) scoring, determine that symptom improves situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Effective: clinical symptoms, sign turn for the better by and large; Effective: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.4 statistical analysis: SPSS 13.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data t checks, enumeration data χ
2inspection.
2 results
2.1 vaginal symptoms improve situations: after medication 5d, matched group 69.81%(37/51) patient, and washout group and all case vagina drying of powder group, dyspareunia symptom all start the improvement that obtains in various degree.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and pale, the flushing in surface and bleeding are clearly better.According to vaginal health standards of grading, vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, secretions 5 project score values.Before washout group patient medication, scoring is 8.27 ± 1.74, and average of marking after medication 14d is 14.26 ± 1.93.Before powder group patient medication, scoring is 9.15 ± 2.62, and average of marking after medication 14d is 17.53 ± 2.62.Compare before and after medication, after two groups of patient treatments, vaginal health scoring is all obviously increased (P<0.05).
2.2 3 groups of Comprehensive Clinical comparitive study: after medication 14d, matched group cure rate, obvious effective rate, effective percentage, inefficiency are respectively 20.75%, 35.85%, 35.85%, 7.55%; The cure rate of washout group, obvious effective rate, effective percentage, inefficiency are respectively 56.60%, 33.96%, 9.43%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 70.37%, 18.52%, 11.11%, 0.00%.Three groups are compared, and the cure rate of washout group and powder group, total effective rate are apparently higher than matched group (P<0.05), and the cure rate of powder group is apparently higher than washout group (P<0.05).
2.3 adverse reaction rates: three groups of patients all do not occur obvious adverse reaction.
2.4 relapse rates: in 3 months, matched group has 11.32%(6/53) case appearance recurrence, washout group relapse rate is 3.77%(2/53), powder group is 1.85%(1/54).
3. conclusion.
This result of study shows, and washout group of the present invention and powder group treatment atrophic vaginitis total effective rate are 100%, and the cure rate of powder group is higher than washout group.Have the advantage that untoward reaction is comparatively light, safety is higher.And relapse rate is low in 3 months.
Claims (1)
1. an atrophic vaginitis lotion preparation method, it is characterized in that Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Flos Magnoliae Amoenae 6 ~ 12 parts, Herba Taxilli 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Ramulus Cinnamomi 10 ~ 25 parts of mixing and water addings decoctions, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges and obtains lotion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310267809.6A CN103341092B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder for treating atrophic vaginitis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310267809.6A Division CN103341092B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder for treating atrophic vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104815243A true CN104815243A (en) | 2015-08-05 |
Family
ID=49275952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510279340.7A Pending CN104815243A (en) | 2013-07-01 | 2013-07-01 | Preparation method of external washing liquid for atrophic vaginitis |
| CN201310267809.6A Expired - Fee Related CN103341092B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder for treating atrophic vaginitis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310267809.6A Expired - Fee Related CN103341092B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder for treating atrophic vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104815243A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316269A (en) * | 2013-07-01 | 2013-09-25 | 付海霞 | Medicine composition for treating primary enuresis |
| CN103316258B (en) * | 2013-07-01 | 2015-06-03 | 青岛市肿瘤医院 | Medicine composition for treating infantile vaginitis |
| CN112088010A (en) | 2018-05-04 | 2020-12-15 | 宝洁公司 | Compositions and methods for treating vaginal dryness |
| CN112135621A (en) * | 2018-05-04 | 2020-12-25 | 宝洁公司 | Compositions and methods for treating vaginal atrophy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686392A (en) * | 2005-04-12 | 2005-10-26 | 北京荔博园医药研究所 | Medicinal composition for treating elytritis, preparation and its quality control method |
| CN102145064A (en) * | 2011-04-18 | 2011-08-10 | 李佃场 | Traditional Chinese medicine composition for treating senile vaginitis and preparation method thereof |
| CN103071096A (en) * | 2013-01-30 | 2013-05-01 | 李秀娟 | External preparation for treating senile vaginitis and preparation method of external preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262296C (en) * | 2003-03-13 | 2006-07-05 | 哈尔滨欧替药业股份有限公司 | Medicine composition, preparing method and use for preparing gynacecopathia medicine |
| CN102727779B (en) * | 2012-07-04 | 2013-09-25 | 王海霞 | Pharmaceutical composition for treating ovarian cysts and preparation method thereof |
-
2013
- 2013-07-01 CN CN201510279340.7A patent/CN104815243A/en active Pending
- 2013-07-01 CN CN201310267809.6A patent/CN103341092B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686392A (en) * | 2005-04-12 | 2005-10-26 | 北京荔博园医药研究所 | Medicinal composition for treating elytritis, preparation and its quality control method |
| CN102145064A (en) * | 2011-04-18 | 2011-08-10 | 李佃场 | Traditional Chinese medicine composition for treating senile vaginitis and preparation method thereof |
| CN103071096A (en) * | 2013-01-30 | 2013-05-01 | 李秀娟 | External preparation for treating senile vaginitis and preparation method of external preparation |
Non-Patent Citations (3)
| Title |
|---|
| 刘敏如等主编: "《中医妇产科学》", 31 October 2001, 人民卫生出版社 * |
| 程秋生编著: "《皮肤病性病中医洗渍疗法》", 31 March 2004, 科学技术文献出版社 * |
| 黄露芬等: "老年性***炎的中医药治疗概况", 《福建中医学院学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103341092A (en) | 2013-10-09 |
| CN103341092B (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN101194998B (en) | Chinese medicine for treating diabetes | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN112717113B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and paste formula and application thereof | |
| CN104771578A (en) | Traditional Chinese medicine for treating allergic rhinitis | |
| CN104784549A (en) | Traditional Chinese medicine for treating allergic rhinitis | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN104840902A (en) | Traditional Chinese medicine preparation for treating ovarian tumor | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis | |
| CN103316258B (en) | Medicine composition for treating infantile vaginitis | |
| CN105125964A (en) | Traditional Chinese medicine preparation for treating pelvic peritonitis and preparation method thereof | |
| CN104606638A (en) | Medicine for treating damp-heat type acute eczema and preparation method thereof | |
| CN104225094A (en) | Traditional Chinese medicine preparation for treating Behcet's syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150805 |